Progress in research of prophylactic therapy in contacts of rifampicin-resistant tuberculosis patients.
10.3760/cma.j.cn112338-20220729-00673
- Author:
Zhan WANG
1
;
Wen Jin WANG
1
;
Xiao Yan DING
2
;
Peng LU
2
;
Li Mei ZHU
2
;
Qiao LIU
2
;
Wei LU
1
Author Information
1. Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing 210009, China Department of Epidemiology for School of Public Health, Nanjing Medical University, Nanjing 211166, China.
2. Department of Chronic Communicable Disease, Center for Disease Control and Prevention of Jiangsu Province, Nanjing 210009, China.
- Publication Type:Journal Article
- MeSH:
Humans;
Rifampin/therapeutic use*;
Tuberculosis, Multidrug-Resistant/prevention & control*;
Tuberculosis/drug therapy*;
Latent Tuberculosis/chemically induced*;
China;
Antitubercular Agents/therapeutic use*
- From:
Chinese Journal of Epidemiology
2023;44(3):470-476
- CountryChina
- Language:Chinese
-
Abstract:
Tuberculosis (TB) prophylactic therapy for latent infection, which can reduce the risk for the development of active TB, is an important measure in TB control. China recommends prophylactic therapy for latent tuberculosis infection (LTBI) in some key populations to reduce the risk for TB. Contacts of patients with multi-drug and rifampicin-resistant TB (MDR/RR-TB) are at high risk for the infection with drug-resistant pathogen, however, no unified prophylactic therapy regimen has been recommended for LTBI due to exposure to MDR/RR-TB patients. This paper summarizes the current MDR/RR-TB prophylactic therapy regimen and its protection effect based on the results of the retrieval of literature, guidelines, expert consensus and technical specifications to provide reference for the prevention and control of LTBI.
